文献速递临床试验与 GCP

饮用可乐治疗食管食物团块嵌顿的疗效:开放标签、多中心、随机对照试验

Efficacy of cola ingestion for oesophageal food bolus impaction: open label, multicentre, randomised controlled trial.
PubMed 文献 · BMJ · 2023-12-11

这项开放标签多中心随机对照试验在荷兰五家医院急诊科纳入51例完全性食管食物团块嵌顿成人,比较饮用可乐(28例,每次25 mL、总量不超过200 mL)与等待自发通过(23例)的疗效。可乐组症状改善17/28(61%)与对照组14/23(61%)无差异(OR 1.00,95%CI 0.33–3.1,P>0.99),完全通过率两组亦无显著差异。作者认为可乐未提高改善率,但可考虑作为一线治疗且不应延迟内镜处理。

要点

  • 可乐组症状改善17/28(61%)与对照组14/23(61%)无差异(OR 1.00,95%CI 0.33–3.1,P>0.99)。
  • 完全通过率可乐组12/28(43%) vs 对照组8/23(35%),差异未达统计学显著(P=0.58)。
  • 可乐组6例(21%)出现饮用后暂时性不适,无严重不良事件。

核心结论

  • 本研究中饮用可乐未使完全性食管食物团块嵌顿的改善率升高。
  • 鉴于治疗组无不良事件且部分病例治疗后缓解,可乐可考虑作为一线治疗,但不应延迟任何内镜处理计划。

研究设计与样本

  • 开放标签、多中心、随机对照试验,在荷兰五家二级和三级医院急诊科进行,时间为2019年12月22日至2022年6月16日。
  • 纳入51例完全性食管食物团块嵌顿成人,定义为进食后突然无法咽下唾液;排除摄入含骨肉类者及美国麻醉医师协会(ASA)分级IV级或以上者。
  • 干预组28例按指示每次饮用25 mL杯装可乐,间隔饮用,最大总量200 mL;对照组23例等待自发通过。
  • 两组若症状未完全缓解,按现行指南行内镜取出:完全梗阻6小时内,部分梗阻24小时内;症状完全缓解者需择期诊断性内镜。

主要发现

  • 主要结局症状改善(完全与部分通过合计)可乐组17/28(61%) vs 对照组14/23(61%),OR 1.00(95%CI 0.33–3.1),相对风险降低0.0(95%CI -0.55–0.36),P>0.99。
  • 完全通过可乐组12/28(43%) vs 对照组8/23(35%),OR 1.4(95%CI 0.45–4.4),相对风险降低-0.23(95%CI -1.5–0.39),P=0.58,差异未达统计学显著。
  • 无严重不良事件发生;干预组6例(21%)在饮用可乐后出现暂时性不适。

临床怎么用

  • 作者认为可乐可考虑作为一线治疗,但不应延迟任何内镜处理计划。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the efficacy and safety of cola in resolving complete oesophageal food bolus impaction. DESIGN: Open label, multicentre, randomised controlled trial. SETTING: Emergency departments of five Dutch hospitals at the secondary and tertiary level, between 22 December 2019 and 16 June 2022. PARTICIPANTS: 51 adults presenting with complete oesophageal food bolus impaction, defined as a sudden inability to pass saliva after consumption of foods. Patients who ingested meat that contained bones, and patients with an American Society of Anesthesiologists (ASA) physical status classification of IV or higher were excluded. INTERVENTIONS: 28 patients in the intervention group were instructed to consume 25 mL cups of cola at intervals up to a maximum total volume of 200 mL. 23 patients in the control group awaited spontaneous passage. In either group, if complete resolution of symptoms did not occur, endoscopic removal was performed following current guidelines: within 6 hours for patients with complete obstruction, and within 24 hours for partial obstruction. In case of complete resolution of symptoms, elective diagnostic endoscopy was required. MAIN OUTCOME MEASURES: Improvement of oesophageal food bolus obstruction as reported by patients (ie, aggregate of complete and partial passage), and evaluation of complete passage. The secondary outcome was any intervention related adverse event. RESULTS: Cola did not have a meaningful effect on the improvement of food bolus obstruction (17/28 (61%) intervention v 14/23 (61%) control; odds ratio 1.00, 95% confidence interval 0.33 to 3.1; relative risk reduction 0.0, 95% confidence interval -0.55 to 0.36; P>0.99). Complete passage was reported more often in the intervention group but this difference was not significant (12/28 (43%) intervention v 8/23 (35%) control; odds ratio 1.4 (0.45 to 4.4); relative risk reduction -0.23 (-1.5 to 0.39); P=0.58). No severe adverse events occurred. However, six (21%) patients in the intervention group experienced temporary discomfort after drinking cola. CONCLUSIONS: In this study, cola consumption did not lead to a higher rate of improvement of complete oesophageal food bolus impaction. Given the lack of adverse events in the treatment group and some events of resolution after treatment, cola might be considered as a first line treatment, but should not delay any planning of endoscopic management. TRIAL REGISTRATION: Netherlands Trial Register (currently International Clinical Trial Registry Platform) NL8312.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Tiebie EG, Baerends EP, Boeije T, et al. Efficacy of cola ingestion for oesophageal food bolus impaction: open label, multicentre, randomised controlled trial. BMJ. 2023. PMID: 38081653. doi:10.1136/bmj-2023-077294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。